Addressing the Elephant in the Room: A Hard Look at Metrics, Legal, Payers, and Other Leading Obstacles Facing the Sustainability of Patient Engagement
Global Patient Engagement Leader
Janssen Pharmaceutical Companies of Johnson & Johnson, United States
As the industry continues to evolve and incorporate the patient’s voice into drug development - ultimately toward the stage of regular and continuous integrative collaboration - this session will discuss how it’s essential to openly assess and discuss common topics and challenges that may impact the long-term sustainability of patient engagement.
Learning Objective : Identify the needs of private payers when defining the value of healthcare treatments and interventions; Describe the legal, regulatory and compliance considerations that biopharmaceutical companies must address to develop and execute sustainable, ethical and compliant patient engagement initiatives; Explore methodologies that biopharmaceutical companies are using to measure internal changes related to regularly, efficiently, and successfully implementing patient-centric solutions.